Abstract | OBJECTIVE: MATERIALS AND METHODS: Enrolled dogs had exhibited control of atopic dermatitis on oclacitinib for at least 6 months before, and continuing throughout, the study. Dogs with non-seasonal pruritus were blindly randomised to receive either SF68 (1×108 colony forming units/g orally twice daily) or placebo for 12 weeks. After 8 weeks of supplementation, oclacitinib dose was decreased by approximately 25%, aiming to maintain and reduce the clinical disease scores. RESULTS: Supplementation with SF68 was associated with no difference in oclacitinib dose reduction versus placebo in 21 client-owned dogs with atopic dermatitis. Clinical disease scores were not different between groups at study completion. CLINICAL SIGNIFICANCE: Further larger-scale studies are warranted to investigate optimal strain(s), dosing and duration of probiotic supplementation as an adjunctive strategy in management of canine atopic dermatitis.
|
Authors | C Yamazaki, W Rosenkrantz, C Griffin |
Journal | The Journal of small animal practice
(J Small Anim Pract)
Vol. 60
Issue 8
Pg. 499-506
(Aug 2019)
ISSN: 1748-5827 [Electronic] England |
PMID | 31257599
(Publication Type: Journal Article)
|
Copyright | © 2019 British Small Animal Veterinary Association. |
Chemical References |
- Dermatologic Agents
- Pyrimidines
- Sulfonamides
- oclacitinib
|
Topics |
- Animals
- Dermatitis, Atopic
(veterinary)
- Dermatologic Agents
(therapeutic use)
- Dog Diseases
(drug therapy)
- Dogs
- Enterococcus faecium
- Pilot Projects
- Pyrimidines
- Sulfonamides
|